Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lindén, B.
Right arrow Articles by Bluhmki, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lindén, B.
Right arrow Articles by Bluhmki, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

A Double-Blind Study to Compare the Efficacy and Safety of Meloxicam 15 mg with Piroxicam 20 mg in Patients with Osteoarthritis of the HIP

B. Lindén*, M. Distel{dagger} and E. Bluhmki

* Eksjö Hospital S-575 81 Eksjö, Sweden
{dagger} Dr Karl Thomae GmbH, Birkendorfer Straβe 65 88397 Biberachl Riss, Germany

Correspondence to: Correspondence to: B. Lindén, Department of Orthopaedic Surgery, Eksjô Hospital, S-575 81 Eksjô, Sweden.


  Abstract

Meloxicam 15 mg once daily (n = 128) was compared with piroxicam 20 mg (n = 127) in this 6 week, double-blind, parallel-group, randomized, multicentre study in out-patients with symptomatic osteoarthritis (OA) of the hip. Assessments of pain, global efficacy and global tolerance were made on a 10 cm horizontal visual analogue scale; severity of OA was evaluated by Lequesne's index. Efficacy results showed significant improvement compared with baseline, with no significant difference between meloxicam 15 mg and piroxicam 20 mg. The type and frequency of adverse events were comparable for the two drugs. The most frequent events reported were gastrointestinal (GI) disorders, occurring in 21 and 23% of meloxicam and piroxicam patients respectively. The global tolerance assessment by patients at the end of treatment favoured meloxicam. In conclusion, meloxicam at a dose of 15 mg/day is comparable in efficacy and safety to piroxicam 20 mg.

KEY WORDS: Meloxicam, Piroxicam, Osteoarthritis, NSAID, Cyclooxygenase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.